➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Mallinckrodt

Last Updated: March 6, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,618,594

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,618,594 protect, and when does it expire?

Patent 7,618,594 protects GENOSYL and is included in one NDA.

This patent has nine patent family members in five countries.

Summary for Patent: 7,618,594
Title:Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Abstract: A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.
Inventor(s): Rounbehler; David R. (Las Cruces, NM), Fine; David H. (Cocoa Beach, FL)
Assignee: GeNO LLC (Cocoa, FL)
Application Number:11/276,610
Patent Claim Types:
see list of patent claims
Formulation; Delivery; Device;

Drugs Protected by US Patent 7,618,594

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vero Biotech GENOSYL nitric oxide GAS;INHALATION 202860-001 Dec 20, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,618,594

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005277397   Start Trial
Canada 2576957   Start Trial
European Patent Office 1789119   Start Trial
European Patent Office 2724742   Start Trial
Japan 2008510675   Start Trial
Japan 2012179365   Start Trial
Japan 5421530   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Dow
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.